MX2009008334A - Esteroides que liberan oxido nitrico. - Google Patents

Esteroides que liberan oxido nitrico.

Info

Publication number
MX2009008334A
MX2009008334A MX2009008334A MX2009008334A MX2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A MX 2009008334 A MX2009008334 A MX 2009008334A
Authority
MX
Mexico
Prior art keywords
formula
nitric oxide
oxide releasing
iii
group
Prior art date
Application number
MX2009008334A
Other languages
English (en)
Spanish (es)
Inventor
Ennio Ongini
Stefano Biondi
Francesa Benedini
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MX2009008334A publication Critical patent/MX2009008334A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009008334A 2007-02-05 2008-01-28 Esteroides que liberan oxido nitrico. MX2009008334A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89937607P 2007-02-05 2007-02-05
US92945607P 2007-06-28 2007-06-28
PCT/EP2008/050938 WO2008095806A1 (en) 2007-02-05 2008-01-28 Nitric oxide releasing steroids

Publications (1)

Publication Number Publication Date
MX2009008334A true MX2009008334A (es) 2009-08-12

Family

ID=39232800

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008334A MX2009008334A (es) 2007-02-05 2008-01-28 Esteroides que liberan oxido nitrico.

Country Status (15)

Country Link
US (4) US8933062B2 (enExample)
EP (3) EP2109617A1 (enExample)
JP (1) JP5216782B2 (enExample)
KR (1) KR20090107525A (enExample)
CN (1) CN101652380A (enExample)
AU (1) AU2008213046B2 (enExample)
BR (1) BRPI0807078A2 (enExample)
CA (3) CA2677441C (enExample)
ES (1) ES2601102T3 (enExample)
IL (1) IL199815A (enExample)
MX (1) MX2009008334A (enExample)
NZ (1) NZ579067A (enExample)
RU (1) RU2442790C2 (enExample)
WO (3) WO2008095809A1 (enExample)
ZA (1) ZA200905067B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011243947A1 (en) 2010-04-23 2012-12-06 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
US8846723B2 (en) 2010-07-29 2014-09-30 Eastman Chemical Company Esters of O-substituted hydroxy carboxylic acids and preparations thereof
KR20140103099A (ko) 2011-10-12 2014-08-25 아센디스 파마 옵탈몰로지 디비젼 에이/에스 안구 병태의 예방 및 치료
EP2729220B1 (en) * 2011-12-20 2015-11-04 Oriflame Research and Development Ltd. Compounds with anti-aging activities
WO2014056915A1 (en) 2012-10-11 2014-04-17 Ascendis Pharma A/S Diagnosis, prevention and treatment of diseases of the joint
CA2897571C (en) 2013-01-21 2018-12-18 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
RU2545416C1 (ru) * 2014-02-18 2015-03-27 Ксения Юрьевна Еременко Способ лечения возрастной макулярной дистрофии
CN103880907A (zh) * 2014-03-11 2014-06-25 天津金耀集团有限公司 丁酸氢化可的松半水合物
AU2017359043B2 (en) 2016-11-08 2022-06-16 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
KR20200007905A (ko) 2017-05-18 2020-01-22 리제너론 파마슈티칼스 인코포레이티드 사이클로덱스트린 단백질 약물 접합체
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
EA202091672A1 (ru) 2018-01-08 2021-02-01 Регенерон Фармасьютикалз, Инк. Стероиды и их антитело-конъюгаты
WO2019217591A1 (en) 2018-05-09 2019-11-14 Regeneron Pharmaceuticals, Inc. Anti-msr1 antibodies and methods of use thereof
WO2020047496A1 (en) * 2018-08-31 2020-03-05 Aerie Pharmaceuticals, Inc. Isoquinoline-steroid conjugates and uses thereof
WO2022135332A1 (zh) * 2020-12-21 2022-06-30 映恩生物制药（苏州）有限公司 一种甾体偶联物
JP7687973B2 (ja) * 2022-01-24 2025-06-03 芳弘 二村 フィブロネクチン活性化作用を介した表皮細胞増殖作用を呈するジテルペン誘導体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3183252A (en) 1963-09-05 1965-05-11 Syntex Corp 16-nitratoalkyl-pregnanes
US3494941A (en) * 1967-12-04 1970-02-10 American Home Prod Nitrate esters of 17beta-(hydroxyalkoxy)steroid 3-ols,3-ones and 3-amidinohydrazones
HU164115B (enExample) 1971-05-07 1973-12-28
IT1285770B1 (it) * 1996-10-04 1998-06-18 Nicox Sa Composti corticoidei
IT1311922B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
ITMI20020148A1 (it) * 2002-01-29 2003-07-29 Nicox Sa Nuovi corticosteroidi
EP1336602A1 (en) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
AU2006286838C1 (en) * 2005-09-02 2013-05-02 Ferrer Internacional S.A. Nitrooxy derivatives of glucocorticoids

Also Published As

Publication number Publication date
CA2677441C (en) 2016-04-12
EP2109617A1 (en) 2009-10-21
IL199815A (en) 2015-03-31
EP2118120B1 (en) 2016-10-05
AU2008213046A1 (en) 2008-08-14
ZA200905067B (en) 2010-04-28
US8933062B2 (en) 2015-01-13
ES2601102T3 (es) 2017-02-14
US20100234334A1 (en) 2010-09-16
RU2009132993A (ru) 2011-03-20
WO2008095809A1 (en) 2008-08-14
CN101652380A (zh) 2010-02-17
IL199815A0 (en) 2010-04-15
RU2442790C2 (ru) 2012-02-20
JP2010517955A (ja) 2010-05-27
CA2677290A1 (en) 2008-08-14
WO2008095808A1 (en) 2008-08-14
BRPI0807078A2 (pt) 2014-04-08
JP5216782B2 (ja) 2013-06-19
US20100041633A1 (en) 2010-02-18
EP2109618A1 (en) 2009-10-21
US20150105547A1 (en) 2015-04-16
CA2677441A1 (en) 2008-08-14
CA2677442A1 (en) 2008-08-14
KR20090107525A (ko) 2009-10-13
NZ579067A (en) 2012-02-24
EP2118120A1 (en) 2009-11-18
US20100093685A1 (en) 2010-04-15
AU2008213046B2 (en) 2013-02-14
WO2008095806A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
MX2009008334A (es) Esteroides que liberan oxido nitrico.
WO2012116290A3 (en) Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
WO2009075835A8 (en) CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
NZ590782A (en) 6-Amino-2-{ [(1S)-1-methylbutyl]oxy} -9-[5-(piperidin-1-yl)pentyl]-7,9-dihydro-8H-purin-8-one and pharmaceutical uses thereof
MX2009004616A (es) Metodos de tratamiento hormonal que utilizan regimenes de ciclo extendido de dosis ascendente.
WO2009102428A3 (en) 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
WO2008106128A3 (en) CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
CL2008001982A1 (es) Acido (2s)-2-{[3´-cloro-4´-[2,2-dimetilpirrolidin-1-il) carbonil]-5-fluorobifenil-2-il]oxi}propanoico y su sal 2-metilpropan-2-amina; formas cristalinas de la sal y del acido libre; compuestos intermediarios; y uso en el tratamiento de asma, rinitis y enfermedad pulmonar obstructiva cronica.
WO2008024497A3 (en) INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
UA94909C2 (ru) Фармацевтическая композиция нейроактивного стероида и ее применение
CO6251311A2 (es) Proceso para la preparacion de acido 5-bifenil-4-amino-2-metil pentanoico
WO2009048119A1 (ja) 高機能化キメラ蛋白質を含有する医薬組成物
JP2010510210A5 (enExample)
NZ709211A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
JP2008546694A5 (enExample)
PH12015501100B1 (en) Novel compounds
SG10201900504XA (en) Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases
MX2011013648A (es) Nuevos compuestos, composiciones farmaceuticas y metodos relacionados con ellos.
WO2009127669A3 (en) Ido inhibitors and therapeutic uses thereof
MX352647B (es) Metodo para temporizar una colonoscopia en donde se administra una composicion de picosulfato.
WO2009099998A3 (en) Therapeutic treatment for lung conditions
WO2011050095A3 (en) Prevention and treatment of post-operative cognitive dysfunction (pocd)
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
IN2012DN01232A (enExample)
AU2013257482B2 (en) Methods and compositions for administration of oxybutynin

Legal Events

Date Code Title Description
FG Grant or registration